S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales

X4 Pharmaceuticals (XFOR) Stock Forecast & Price Target

$1.00
+0.04 (+4.19%)
(As of 02/27/2024 ET)

X4 Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 4 Analyst Ratings

Analysts' Consensus Price Target

$3.20
221.41% Upside
High Forecast$5.00
Average Forecast$3.20
Low Forecast$1.00
TypeCurrent Forecast
2/28/23 to 2/28/24
1 Month Ago
1/29/23 to 1/29/24
3 Months Ago
11/30/22 to 11/30/23
1 Year Ago
2/28/22 to 2/28/23
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$3.20$3.20$3.50$6.33
Predicted Upside221.41% Upside228.22% Upside241.56% Upside363.45% Upside
Get X4 Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.


XFOR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

XFOR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

X4 Pharmaceuticals Stock vs. The Competition

TypeX4 PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside221.41% Upside1,757.74% Upside7.73% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/12/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Patel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$3.00 ➝ $1.00+64.99%
8/11/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$3.00+185.71%
5/17/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$4.00 ➝ $5.00+146.56%
3/24/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$5.00 ➝ $4.00+377.78%
3/22/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Kluska
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$3.00+240.91%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 05:59 AM ET.












XFOR Price Target - Frequently Asked Questions

What is X4 Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for X4 Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 3 buy ratings for XFOR. The average twelve-month price prediction for X4 Pharmaceuticals is $3.20 with a high price target of $5.00 and a low price target of $1.00. Learn more on XFOR's analyst rating history.

Do Wall Street analysts like X4 Pharmaceuticals more than its competitors?

Analysts like X4 Pharmaceuticals more than other Medical companies. The consensus rating score for X4 Pharmaceuticals is 2.75 while the average consensus rating score for medical companies is 2.68. Learn more on how XFOR compares to other companies.

Is X4 Pharmaceuticals being downgraded by Wall Street analysts?

Over the previous 90 days, X4 Pharmaceuticals's stock had 1 downgrade by analysts.

Does X4 Pharmaceuticals's stock price have much upside?

According to analysts, X4 Pharmaceuticals's stock has a predicted upside of 228.22% based on their 12-month stock forecasts.

What analysts cover X4 Pharmaceuticals?

X4 Pharmaceuticals has been rated by B. Riley in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:XFOR) was last updated on 2/28/2024 by MarketBeat.com Staff